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RESEARCH ARTICLE
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Abstract
This study utilized magnetic resonance imaging (MRI) to monitor the real-time
status of the urinary bladder in normal and diseased states following
cyclophosphamide (CYP)-induced cystitis, and also examined the role of the
phosphoinositide 3-kinase (PI3K) pathway in the regulation of urinary bladder
hypertrophy in vivo. Our results showed that under MRI visualization the urinary
bladder wall was significantly thickened at 8 h and 48 h post CYP injection. The
intravesical volume of the urinary bladder was also markedly reduced. Treatment of
the cystitis animals with a specific PI3K inhibitor LY294002 reduced cystitis-induced
bladder wall thickening and enlarged the intravesical volumes. To confirm the MRI
results, we performed H&E stain postmortem and examined the levels of type I
collagen by real-time PCR and western blot. Inhibition of the PI3K in vivo reduced
the levels of type I collagen mRNA and protein in the urinary bladder ultimately
attenuating cystitis-induced bladder hypertrophy. The bladder mass calculated
according to MRI data was consistent to the bladder weight measured ex vivo
under each drug treatment. MRI results also showed that the urinary bladder from
animals with cystitis demonstrated high magnetic signal intensity indicating
considerable inflammation of the urinary bladder when compared to normal
animals. This was confirmed by examination of the pro-inflammatory factors
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showing that interleukin (IL)-1a, IL-6 and tumor necrosis factor (TNF)a levels in the
urinary bladder were increased with cystitis. Our results suggest that MRI can be a
useful technique in tracing bladder anatomy and examining bladder hypertrophy in
vivo during disease development and the PI3K pathway has a critical role in
regulating bladder hypertrophy during cystitis.

Introduction
The urinary bladder is constituted by four basic layers of tissues, namely the
urothelium, the suburothelium space, the detrusor smooth muscle layer, and the
outermost serous membrane. The urothelium layer acts as a permeability barrier
protecting underlying tissues against noxious urine components. The lamina
propria is rich in nerves, blood vessels, connective tissues, and also contains a
variety of immune cells. In response to noxious stimuli or injury of the urinary
bladder, destruction of the urothelium architecture occurs which is accompanied
by enhanced vasodilation, and accumulation and infiltration of immune
substances thereby causing excessive release of inflammatory mediators,
erythematous swelling and hemorrhage of the bladder [1, 2, 3, 4, 5]. Dysfunctional
pathology of the smooth muscle layer in the bladder wall is tightly related to poor
compliance of the urinary bladder and detrusor instability which is often
attributable to bladder wall thickening caused by excessive deposition of fibrotic
connective tissues and detrusor smooth muscle hyperplasia and/or hypertrophy
[1, 6, 7]. In inflammatory state, the serous membrane may also become thickened
with subserous cellular tissue infiltration.
The urinary bladder wall thickening is often seen in patients and animals with
cystitis, bladder outlet obstruction (BOO), and sometimes with neurological
disorders [6, 8, 9, 10]. Previous studies with an animal model of cystitis induced by
intraperitoneal injection of cyclophosphamide (CYP) or intravesical instillation of
acrolein, a metabolite of CYP [11], demonstrate that the weight of the urinary
bladder is dramatically increased in the diseased animals when compared to
healthy controls [6, 12, 13]. Several factors are suggested to have critical roles in
bladder pathology during chemically induced cystitis. These factors include but
are not limited to growth factors such as nerve growth factor (NGF) [14, 15] and
transforming growth factor-beta (TGF)b [14, 16], cannabinoids [17, 18, 19],
cytokines and chemokines [16, 20, 21, 22], muscarinic and purinergic systems
[23, 24, 25, 26], and a variety of inflammatory mediators [27, 28]. The cellular
responses of these factors are mediated by specific receptors such as receptor
tyrosine kinase (RTK) or G-protein coupled receptor (GPCR), and can converge
on the PI3K and Akt pathways [29, 30, 31, 32]. In turn, activation of the PI3K/Akt
pathway also leads to gene expression and cellular growth and survival [33, 34].
Previous studies by us and others show that in CYP-induced cystitis the activity of
Akt is increased in the urinary bladder [6], dorsal root ganglia [35], and spinal

PLOS ONE | DOI:10.1371/journal.pone.0114536 December 8, 2014

2 / 17

PI3K Regulates Bladder Hypertrophy Examined by MRI

cord [36]. Inhibition of the PI3K-mediated Akt activation reverses cystitisinduced spinal central sensitization [36] as well as bladder overactivity examined
by cystometry [37]. In the understanding of molecular mechanisms underlying
the regulation of bladder hypertrophy, the role of the PI3K/Akt pathway has not
been investigated and is the focus of this study.
Magnetic resonance imaging (MRI), also called magnetic resonance tomography, is widely used in clinical settings to investigate the anatomy and function
of the body in both health and disease. MRI has been widely used for visualization
of internal structures in the body. In comparison with computed tomography
(CT) scan, MRI is better in determining the depth of wall invasion in bladder
tumors [38] with the greatest advantage in differentiating between a normal
bladder and other pathologic conditions including inflammatory and congestive
processes [39]. In humans, MRI is used to diagnose bladder hypertrophy caused
by BOO or cystitis [40, 41]. In a recent pre-clinical study T2-weighted MRI is used
to visualize the rat bladder with partial BOO before and after mesenchymal stem
cell transplant [42], which shows that bladder wall thickness is correlated with the
expression level of collagen and TGF-b protein in the urinary bladder [42].
The present study was undertaken to examine the role of the PI3K inhibition in
urinary bladder hypertrophy caused by cystitis by combining an in vivo approach
of MR imaging and ex vivo approaches of histological and molecular analysis.
Excessive cellular growth, fibrosis and inflammation are key contributing factors
causing bladder hypertrophy in cystitis. The PI3K/Akt pathway functioning as a
master switch in mediating multi-signaling networks may govern the growth
promoting processes thereby regulating bladder hypertrophy.

Materials and Methods
Experimental animals and ethics statement
Adult male rats weighing 150–200 g were used for all studies. All experimental
protocols involving animal use were approved by the Institutional Animal Care
and Use Committee at the Virginia Commonwealth University (IACUC #
AM10315), and at the Fudan University. Animal care was in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) and National Institutes of Health guidelines. All efforts were made to
minimize the potential for animal pain, stress or distress as well as to reduce the
number of animals used.

Induction of cystitis
Cystitis was induced in rats by intraperitoneal injection of cyclophosphamide
(CYP, Sigma-Aldrich, St. Louis, MO) at a single dose of 150 mg/kg body weight.
The animals were allowed to survive for 8 or 48 hours (h). In MRI studies, each
rat served as its own control before and after CYP treatment. For other studies,
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control rats received volume-matched injections of saline. All injections were
performed under isoflurane (2%) anesthesia.

Drug treatment of animals
To block the PI3K/Akt pathway in vivo, an intraperitoneal injection of a PI3K
inhibitor LY294002 (Calbiochem, dissolved in DMSO as stock and diluted in
saline for injection) at a single dose of 50 mg/kg body weight was made
immediately after CYP injection [36]. The same amount and concentration of
DMSO was used as vehicle control.

Magnetic resonance imaging of the urinary bladder
All MRI measurements were acquired utilizing the Siemens Avanto 1.5 T scanner.
The imaging coil was a phased array coil for rat with inner diameter of 5 cm.
Under anesthesia (2% isoflurane), the animal was placed in the supine position
into the MRI built-in chamber for scanning. A spin-echo T2 weighted plus water
suppression MRI sequence was used with parameters: TR 7500 ms, TE 124 ms, TI
2200 ms, FOV 120 mm2, and slice thickness 2 mm. The images were obtained in
the axial and sagittal planes according to procedures modified from the method
used in human MRI to diagnose bladder hypertrophy caused by bladder outlet
obstruction (BOO) or cystitis [40]. It was shown that it was not necessary to
manually empty the urinary bladder (manually squeezing bladder often causes
wall collapse) to evaluate bladder wall thickening [40]. After the images were
obtained, the outer diameter of the bladder wall (26 tR: total radius), the inner
diameter of the bladder wall (26 iR: intravesical radius), and the thickness of the
wall (direct measurement or tR - iR) were measured with built-in software. Each
parameter was measured at 4 directions (horizontal, vertical, two diagonal) and
averaged. The bladder mass was calculated by subtracting the intravesical volume
from the total vesicle volume and then multiplied by the urinary bladder density
shown as


4=3p | tR3 4=3p | iR3 | r
where tR was total radius, iR was inner radius, and r was the density of the
urinary bladder which was considered as 1 [43].

RNA extraction and quantitative real-time PCR
Total RNA was extracted using a RNA extraction kit RNAqueous (Ambion, TX).
RNA concentration was determined spectrophotometrically. cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
ABI). Following reverse transcription, quantitative real-time PCR was performed
on StepOnePlus Real-Time PCR Systems (Applied Biosystems, ABI) under a
condition of 40 cycles of 95 ˚C for 15 s and 60 ˚C for 1 min, using SYBR Green as
indicator. The level of target mRNA was normalized against the expression of the
internal control 18S in the same sample that was calculated with DCt method. The
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Table 1. Primers used in real-time PCR.
TNFa F(59-39) AGCCCGTAGCCCACGTCGTA
TNFa R(59-39) ATGCCATTGGCCAGGAGGGC
IL-1a F(59-39) CCGCAGCTTTCCCAGAGCTGTT
IL-1a R(59-39) TCATGGAGGGCAGTCCCCGT
IL-6 F(59-39) TGTTGACAGCCACTGCCTTCCC
IL-6 R(59-39) ACTGGTCTGTTGTGGGTGGTATCCT
doi:10.1371/journal.pone.0114536.t001

sequences of primers were listed in Table 1. The expression level of target mRNA
in control group from each independent experiment was considered as 1, and the
relative expression level of target mRNA in experimental groups was adjusted as a
ratio to its control in each independent experiment and expressed as fold changes
(22DDCt-fold).

Western blot
The urinary bladder was freshly dissected out and homogenized in T-per buffer
(Pierce Biotechnology, Rockford, IL) supplemented with protease and phosphatase inhibitor cocktails (Sigma). The protein extracts were subject to centrifugation at 20,200 g for 10 min at 4 ˚C, and the supernatant was removed to a fresh
tube. The protein concentration was determined using Bio-Rad DC protein assay
kit. Proteins were then separated on a 10% SDS-PAGE gel and transferred to a
nitrocellulose membrane. The membrane was blocked with 5% milk in Trisbuffered saline for 1 h and then incubated with a primary antibody against type I
collagen (1:1000, Cell Signaling Technology, Inc.) followed by IRDye secondary
antibody. For internal loading control and normalization, the same membrane
was striped and re-probed with anti-b-actin (1:3000, Sigma). The bands were
visualized with an ODYSSEY infrared imaging system (Li-cor Bioscience).
Densitometric quantification of immunoreactive bands was performed using the
software FluorChem 8800 (Alpha Innotech, San Leabdro, CA).

Hematoxylin and Eosin (H&E) stain
Transverse sections of the urinary bladders (10 mm thickness) from all animals
were stained with an H&E Stain kit according to the protocol provided by the
manufacture (Richard-Allan-Scientific, Kalamazoo, MI). The sections were
examined with a Zeiss brightfield microscope. Three sections were randomly
chosen and four random measurements were made for each animal and averaged
as one point (n). The measurement of the thickness of the bladder wall was made
with software AxioImage built in the Zeiss microscope.
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Statistical analysis
Comparison between control and experimental groups was made by using oneway ANOVA followed by Dunnett’s test to compare each treatment with control,
or Newman-Keuls test to compare all groups. When two groups were compared,
student’s t-test was used. Differences between means at a level of p#0.05 were
considered to be significant.

Results
MRI examination of the urinary bladder in normal and cystitis
animals
The animals were examined under 2% isoflurane without manually expressing the
urinary bladder. The axial and sagittal planes of the urinary bladder were obtained
to better visualize the dome of the urinary bladder (Fig. 1A shows an axial
section). A spin-echo T2-weighted MR sequence revealed that the urinary bladder
in control animals demonstrated as a smooth hollow organ in the pelvis (Fig. 1B).
Our previous studies demonstrated that CYP treatment caused urinary bladder
inflammation and bladder wall thickening examined ex vivo by histology and
molecular approaches [6, 14]. MRI scan of CYP-treated animals provided a better
visualization of the urinary bladder anatomy in vivo in live animals. At 2 h post
CYP treatment the urinary bladder had similar anatomic appearance to that from
control animals (Fig. 1C). At 8 h and 48 h post cystitis induction the entire wall
of the urinary bladder became thicker when compared to control (Fig. 1D and
Fig. 1E).
At each time point following CYP treatment, the muscular layer of the urinary
bladder demonstrated low signal intensity (green arrow). There was no difference
in the signal intensity emitted between the thin and thick detrusor muscular layers
and the differentiation between the control and pathologic states was based on
thickness. The intravesical side of the wall (red arrows) demonstrated high signal
intensity in CYP-treated animals when compared to control, which indicated
congestion and/or inflammation of the urinary bladder according to published
criteria [39, 40, 41]. The serous membrane also demonstrated great congestion/
inflammation/adhesion in CYP-treated animals when compared to control (blue
arrows).
The thickness of the bladder wall including all layers of the bladder structure
was measured using built-in measurement tools showing that CYP cystitis caused
an increase in the thickness of the bladder wall (Fig. 1F). The intravesical volume
was calculated by volume formula based on the measurement of the intravesicle
radius. CYP cystitis also resulted in a decrease in bladder intravesical volume at 8
and 48 h following CYP treatment (Fig. 1G).
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Fig. 1. MRI visualization demonstrated an increase in the thickness of bladder wall and a decrease in
the volume of bladder dome during CYP-induced cystitis. A spin-echo T2-weighted MR sequence was
performed to visualize the urinary bladder in the pelvis on axial sections (A). The same animal was scanned
before (B) and after CYP treatment (C-E). At 2 h after cystitis was induced, the anatomy of the urinary bladder
appeared similar to control. At 8 h and 48 h post cystitis induction, the thickness of the bladder wall was
significantly increased (F) which was accompanied with a decrease in intravesical volume (G). Summary
results were from 5 animals before and after CYP injection. *, p,0.05.
doi:10.1371/journal.pone.0114536.g001

MRI examination of the effects of PI3K inhibition on the urinary
bladder hypertrophy
The PI3K/Akt pathway plays a significant role in regulating bladder function
during cystitis [6, 37, 44]. In the present study, we suppressed the endogenous
PI3K activity by LY294002 and examined the bladder wall thickness by MRI in
order to test whether the PI3K/Akt pathway has a role in cystitis-induced bladder
organ hypertrophy in vivo. Following LY294002 treatment, the thickness of the
bladder wall from cystitis animals was significantly reduced (compare Fig. 2B to
Fig. 2A, areas between green and red circles were bladder walls indicated by red
arrows, summary data Fig. 2C). The intravesical volume was significantly enlarged
in the LY294002 treated cystitis animals when compared to CYP treatment alone
(compare Fig. 2B to Fig. 2A, inside the red circle marked by *, summary data
Fig. 2D).
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Fig. 2. PI3K inhibition with LY294002 attenuated cystitis-induced bladder wall thickening and restored
bladder capacity. The urinary bladders from cystitis animals (8 h, A) and cystitis animals treated with PI3K
inhibitor LY294002 (CYP 8 h + LY, B) were visualized by MRI. Green circle indicated the outer edge of the
urinary bladder (A, B); the pink circle indicated the inner edge of the urinary bladder (A, B). Treatment with
LY294002 prevented bladder wall thickening caused by cystitis (C), and also increased the intravesical
volume during cystitis (D). n54. *, p,0.05.
doi:10.1371/journal.pone.0114536.g002

Confirmation of the effects of PI3K inhibition on preventing
cystitis-induced bladder hypertrophy by histology
The effects of LY294002 on the urinary bladder hypertrophy and inflammation
were further examined by histological techniques. We have previously showed
that CYP cystitis increased the thickness of the bladder wall examined by H&E
stain [6]. To confirm the effects of LY294002 on the thickness of the urinary
bladder examined by MRI, we compared the H&E stain of the urinary bladder
from cystitis animals and those animals also receiving LY294002 treatment
(Fig. 3A, Fig. 3B, and Fig. 3C). Microscopic examination showed that the
thickness of the muscle layer was significantly increased, and the suburothelium
spaces also expanded dramatically after CYP treatment, resulting in a significant
increase in the thickness of the bladder wall (compared Fig. 3B to Fig. 3A,
summary data Fig. 3D). LY294002 treatment greatly reduced the thickness of the
bladder wall when compared to CYP treatment alone (compare Fig. 3C to Fig. 3B,
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Fig. 3. Postmortem examination by H&E showed PI3K inhibition on bladder wall thickening during
cystitis. Transverse sections (10 mm) of the urinary bladder from control (A), cystitis (B) and cystitis with
LY294002 (LY) treatment (C) were stained by H&E (m: muscular layer; u: urothelium; d: bladder dome). The
thickness of the bladder wall was increased by cystitis (D). LY294002 treatment reduced bladder wall
thickness caused by cystitis (D). Bar 5200 mm. n53. *, p,0.05 vs vehicle control. #, p,0.05 vs CYP cystitis.
doi:10.1371/journal.pone.0114536.g003

summary data Fig. 3D). It was apparent that the architecture of the urothelium
was greatly damaged in the cystitis animals (compared Fig. 3B to Fig. 3A) and was
recovered, in part, by LY294002 treatment (compared Fig. 3C to Fig. 3B and
Fig. 3A).

PI3K inhibition reversed cystitis-induced fibrosis and
inflammatory response thereby reducing bladder hypertrophy
Fibrosis is one of the major factors that contribute to urinary bladder hypertrophy
[1]. We also showed that type I collagen, a main component of the extracellular
matrix, was up-regulated in the urinary bladder with cystitis [6]. In bladder
explant culture, the PI3K/Akt pathway was involved in NGF-induced type I
collagen production [6]. Thus, we further examined whether the endogenous
PI3K activity had a role in regulating type I collagen production thereby
regulating bladder cytology and functionality. Trichrome stain showed an increase
in the levels of extracellular matrix in the urinary bladder during cystitis (blue
stain, compare Fig. 4B to Fig. 4A). When cystitis animals were treated with
LY294002, the level of extracellular matrix was lower than those from cystitis
animals (compare Fig. 4C to Fig. 4B). Western blot analysis of type I collagen
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Fig. 4. PI3K inhibition reduced collagen up-regulation by cystitis. Trichrome stain (A-C) showed an
increased amount of extracellular matrix built-up in the urinary bladder at 8 h of cystitis (B, blue stain).
LY294002 (LY) treatment reduced the level of extracellular matrix content in the urinary bladder of cystitis
animals (C). Western blot (D) with a specific antibody recognizing type I collagen showed similar results that
cystitis increased collagen protein expression which was attenuated by LY294002 treatment (E). Real-time
PCR demonstrated that cystitis-induced type I collagen mRNA up-regulation was also inhibited by LY294002
treatment (F). n53. Bar n5200 mm. *, p,0.05 vs vehicle control. #, p,0.05 vs CYP cystitis.
doi:10.1371/journal.pone.0114536.g004

protein level confirmed these observations (Fig. 4D) showing that suppression of
endogenous PI3K activity reduced cystitis-induced type I collagen up-regulation
in the urinary bladder (Fig. 4E). The PI3K/Akt pathway also regulated collagen
expression at the transcriptional level (Fig. 4F).
Inflammation of the urinary bladder was characterized by the production level
of pro-inflammatory factors: tumor necrosis factor (TNF)a (Fig. 5A), interleukins
IL-1a (Fig. 5B) and IL-6 (Fig. 5C). CYP cystitis significantly increased the
expression level of these factors in the urinary bladder. LY294002 treatment
reduced the up-regulation of the pro-inflammatory factors in the urinary bladder
(Fig. 5). These results suggested that the PI3K/Akt pathway was able to regulate
inflammatory responses in vivo during cystitis.
When the collagen production and inflammation were suppressed by LY294002
treatment, the size of the urinary bladder was subsequently reduced in cystitis
animals when compared to CYP treatment alone (Fig. 6). Using the formula
described in the method section, we calculated the bladder mass in vivo based on
the MRI results and demonstrated an increase in the CYP groups and a reduction
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Fig. 5. Cystitis-induced up-regulation of pro-inflammatory factors was attenuated by LY294002
treatment. The levels of tumor necrosis factor alpha (TNFa) (A), interleukin 1a (B) and IL-6 (C) were upregulated by cystitis examined at 8 h post CYP injection. LY294002 (LY) treatment reversed inflammatory
responses in the urinary bladder caused by cystitis. n53. *, p,0.05 vs vehicle control. #, p,0.05 vs CYP
cystitis.
doi:10.1371/journal.pone.0114536.g005

in LY294002 treated groups (Fig. 6A); these numbers were very similar to the wet
weight of the urinary bladder measured ex vivo (Fig. 6B) suggesting that MRI is
reliable in the measurement of bladder hypertrophy in situ.

Discussion
The greatest advantage of magnetic resonance is its ability to differentiate between
a normal urinary bladder, and other pathologic conditions affecting the urinary
bladder, including inflammatory, congestive and neoplastic processes without
sacrificing the animals [39]. The present study utilized this in vivo live technique
to monitor the urinary bladder in real-time and examined the anatomic changes
in the urinary bladder during cystitis in rats and also examined the effects of the
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Fig. 6. PI3K inhibition decreased cystitis-induced increment of bladder weight measured in vitro and in
vivo. The bladder mass was calculated by analyzing MRI data and using a formula described in the
methodology (A). Postmortem measurement of the bladder weight showed an increase in cystitis animals
when compared to control (B); this increment was reduced by LY294002 (LY) treatment (B). n54–5. *, p,0.05
vs vehicle control. #, p,0.05 vs CYP cystitis.
doi:10.1371/journal.pone.0114536.g006

PI3K inhibition on the urinary bladder. MR images showed that cystitis increased
the overall mass of the urinary bladder by increasing the thickness of the bladder
wall and increasing the inflammatory responses shown as increased magnetic
intensity of the bladder lining. The intravesical volume of the urinary bladder was
markedly decreased following CYP treatment. However, intervention with a PI3K
inhibitor LY294002 reduced the bladder mass, the thickness of the bladder wall
and partially restored the capacity of the urinary bladder. Ex vivo histology
confirmed the MRI observation showing the ability of the PI3K inhibitor in
reversing urinary bladder thickening caused by cystitis. Further examination
revealed that the effects of the PI3K inhibition on reducing urinary bladder
hypertrophy were due to its ability in decreasing the degree of fibrosis and
inflammatory responses in the urinary bladder.
MRI techniques have been widely used in humans to examine the internal
structure of soft tissues in normal and diseased states [45, 46]. The magnetic field
acts upon protons found in water within the soft tissue which sends out signals as
radio waves, thus it is especially helpful to collect pictures of internal organs and
muscles that do not show up on x-ray examination. This technique can be used to
scan tissues in the body including pelvic organs [47]. As for the urinary bladder
which contains a large volume of water in the dome and produces high
background signals during visualization of the wall, T2-weigthted MR imaging is
often used for its low signal intensity to differentiate the tissues from the urine and
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the perivesical fat [48, 49]. In the present study, we also used T2-weighted MRI to
examine the thickness of the bladder wall. To better distinguish the tissue
anatomy, we applied water-suppression technique to enhance the signal of the soft
tissue by extensively lowing the signal in the dome. This gave us a better
visualization of the urinary bladder, and provided means to identify the thickness
of the bladder wall. MRI techniques have been successfully used to detect bladder
wall thickness in humans and experimental animals in normal and diseased states
[39, 40, 49, 50]. MRI results show an increase in the thickness of the bladder wall
in patients with BOO or cystitis [40]. In this study in a rat model of chemicallyinduced cystitis, we found that the MRI results were consistent to those examined
ex vivo by histology, suggesting that MRI can be used for this disease model to
detect the real-time changes of the urinary bladder and study drug efficacy during
treatment. In some of our studies, we attempted to manually empty the urinary
bladder and found that the bladder wall was completely collapsed which made it
very difficult to examine the thickness (data not shown). This is consistent to
published studies demonstrating that evaluation of bladder wall thickening with
MRI must require some degree of urinary bladder distention [39, 40]. During
MRI, the urinary bladder is not fully distended and is not ready for micturition.
Thus the intravesical volume obtained by MRI is much smaller than those
obtained by measuring the amount of urine voided through micturition [51].
Cystitis-induced bladder hypertrophy is accompanied by collagen up-regulation [6] and increased inflammatory responses in the urinary bladder. Anatomic
and molecular studies in the present paper demonstrate that the PI3K pathway is
involved in cystitis-induced bladder hypertrophy by up-regulating collagen
mRNA and protein levels, and by increasing the production of pro-inflammatory
factors in the urinary bladder. Activation of PI3K can lead to the activation of Akt,
a downstream effector that is activated in the urinary bladder during cystitis [6]. It
is reported that the PI3K pathway is involved in collagen production in culture
[6]. The regulation of collagen by the PI3K pathway is also found in cultured
human dermal fibroblasts [52], human retinal pigment epithelial cells [53], and
human tenon’s fibroblasts [54]. Our study further demonstrates that the
activation of the PI3K pathway also leads to collagen up-regulation in vivo
because inhibition of the endogenous PI3K activity reverses cystitis-induced type I
collagen up-regulation in the urinary bladder, ultimately reverses cystitis-induced
bladder wall thickening.
The elevated inflammatory response is another major contributing factor to
urinary bladder hypertrophy. Cystoscopy findings show the presence of
glomerulations and Hunner’s ulcers on the bladder wall, scarred or stiff wall with
low compliances and reduced bladder capacity in cystitis patients [55]. Cytokines,
chemokines, prostaglandins, adenosine systems and growth factors are also
examined in the urinary bladder with OAB, DO or cystitis [1, 2, 20, 56]. In
response to bladder irritation, the innermost urothelium layer undergoes
considerable injury with increased apoptosis and accumulation of inflammatory
cells such as mast cells, neutrophils and macrophages accompanied with release of
the inflammatory mediators [56]. The subsequent actions of these factors are to
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modify detrusor smooth muscle mitosis and contractility thus altering the activity
of gene expression and ion channels, regulating cell cycle events and increasing
protein production and deposition of extracellular matrix leading to bladder
hypertrophy. In CYP-induced bladder inflammation and hypertrophy shown in
the present study, the levels of pro-inflammatory factors IL-1a, IL-6 and TNFa are
increased; which is attenuated by administration of the PI3K inhibitor LY294002.
These results suggest that the PI3K pathway also has a role in regulating
inflammatory responses in the urinary bladder.
In summary, the present studies utilizing imaging techniques and molecular
and histologic tools demonstrate that the PI3K has a crucial role in regulating
urinary bladder hypertrophy examined in a cystitis rat model induced by CYP.
The molecular mechanisms underlying the PI3K regulation of bladder
hypertrophy lies in its ability in the regulation of type I collagen up-regulation in
vivo and its role in regulating the production of pro-inflammatory factors.
Intervention of the PI3K pathway may be effective in treatment of bladder
hypertrophy and associated diseases. In the examination of bladder wall
thickening in normal and diseased states, MRI can be used for in vivo
visualization and can also be used as a pre-clinical tool in the evaluation of drug
effects.
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